Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) granted a stock option inducement award to one newly hired employee on August 31, 2026. The option covers an aggregate of 8,400 shares of Akebia common stock at an exercise price of $0.92 per share, equal to the closing price on the grant date. The award was approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to continued service, and have a 10-year term under Akebia’s inducement award program and stock option agreement.
Details
Market move: AKBA +3.77% in the Sep 2 session. inducement option grant
On Sep 2, the first trading day after this news, AKBA closed 3.77% above the previous close. Argus tracked a peak move of +2.4% during that session. Our momentum scanner recorded 10 alerts for this stock that day. Relative volume reached 3.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Shares Granted
- 8,400 shares
- One newly hired employee; August 31, 2026 grant
- Exercise Price
- $0.92 per share
- Equal to the closing price on the grant date
- Vesting Period
- 4 years
- Subject to continued employee service
- First Vesting Tranche
- 25%
- Vests on the first anniversary of the grant date
- Remaining Vesting Tranche
- 75%
- Vests quarterly after the first anniversary
- Option Term
- 10-year term
- Subject to the inducement award program and option agreement
Historical Context
-
Revenue declined and the company reported a net loss amid generic competition.
-
Options covering 61,000 shares were granted to two newly hired employees.
-
Akebia initiated a Phase 2 basket trial of ebribafusp in rare kidney diseases.
-
The company scheduled release of second-quarter 2026 financial results.
-
Options covering 125,600 shares were granted to three new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.